Type 2 diabetes patients who took insulin degludec or insulin glargine attained similar mean HbA1C and fasting plasma glucose levels at 52 weeks, a study found. However, fewer nocturnal hypoglycemic episodes were seen in the degludec-treated patients at one year, compared with those who took glargine. The results were presented at the European Association for the Study of Diabetes meeting.

Related Summaries